3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase 1
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
7
Hematologic Neoplasms
7
Graft vs Host Disease
5
Gliosarcoma
5
Glioblastoma
5
Brain Neoplasms
5
Prostatic Neoplasms
4
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Waldenstrom Macroglobulinemia
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Tuberous Sclerosis
2
Oligodendroglioma
2
Neurofibrosarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioma
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Interventions
Everolimus
2
carbon-11 acetate
1
Sirolimus
1
Simvastatin
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphangioleiomyomatosis
×
Sirolimus
×
Clear all
NCT02061397
2020-08-25
SOS
University of Pennsylvania
Phase 1/2
Completed
10 enrolled
6 charts